Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

New solutions include customized reagents that scale from bench to clinical trials, industrialized lentiviral vector ...

ROCKVILLE, Md.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral ...

The global lentiviral vector CDMO market is projected to grow at a CAGR of 8% over the next five years. This growth is driven by rising demand for gene and cell therapies, an expanding pipeline of ...

The popularity of viral vector-based gene therapies and vaccines is rapidly growing. However, it is often difficult for scientists to ramp up the generation of these vectors to meet their needs at ...

Shenzhen EurekaBio closed a $40 million Series B+ funding to support the commercialization of its EuLV™ Lentiviral Vector Production System. Chengdu Maxvax Biotechnology raised $40 million in a Series ...

The platform can reduce lentiviral vector production timelines from 18 months to less than 7 months Charles River provides viral vector production services ranging from clone construction through good ...

Licensing of a proven stable producer system for lentiviral vector production represents a significant investment in next-generation technology for Genezen, offering its clients immediate access to ...

Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Plasmid DNA and Viral Vector Manufacturing Services With over 20 years of plasmid DNA and viral vector ...